← Leaderboards
Travis Lee Stiles
Novoron Bioscience, Inc.
$2,044,575
Attributed
$4,508,325
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,508,325 · 6
By mechanism
R41$1,881,892 · 3
R43$1,368,905 · 2
R44$1,257,528 · 1
Top collaborators
- Jae K Lee5 shared
- Alban P Gaultier4 shared
- Kenneth S Kosik4 shared
- Robert T Fremeau1 shared
- Steven D Rees1 shared
Most similar at Novoron Bioscience, Inc.
Same institution · by research overlap
- Andrew Taylor Bright$132,277
Others in their field
Top investigators on “Receptor”
- Barton F Haynes · Duke University$182,835,224
- James C. Paulson · Scripps Research Institute$84,068,192
- Asrar B. Malik · University Of Illinois At Chicago$55,280,031
- Anthony O Caggiano · Cognition Therapeutics, Inc.$49,563,751
- Robert J Coffey · Vanderbilt University$48,115,270
- Robert H Vonderheide · University Of Pennsylvania$48,030,034
Research focus
ReceptorResponseNeuronsIn VivoPharmaceutical PreparationsNeuraxisLeadLdl-Receptor Related Protein 1ProteinsDoseCellsTechnologyEventIn VitroMediatingIntravenous AdministrationClinically RelevantPre-ClinicalMyelinLesionRodent ModelBrainSiteTherapeutic Target
Grant awards (14)
Human iPSC neural spheroids to screen for compounds that block tau propagation$1,257,528
R44 · FY2025 · AG · contact PI
A novel approach to restricting the spread of neurofibrillary tau$348,075
R41 · FY2022 · AG · contact PI
A novel approach to restricting the spread of neurofibrillary tau$110,250
R41 · FY2022 · AG · contact PI
A novel approach to restricting the spread of neurofibrillary tau$36,750
R41 · FY2022 · AG · contact PI
A novel approach to restricting the spread of neurofibrillary tau$349,580
R41 · FY2021 · AG · contact PI
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS$354,097
R41 · FY2020 · NS · contact PI
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS$353,084
R41 · FY2019 · NS · contact PI
Assessment of NOVO-118 as a regenerative therapeutic in acute spinal cord injury$347,542
R43 · FY2019 · NS · contact PI
Assessment of NOVO-118 as a regenerative therapeutic in acute spinal cord injury$347,510
R43 · FY2018 · NS · contact PI
RAP as a novel therapeutic to promote remyelination after MS demyelinating event$320,747
R43 · FY2016 · NS · contact PI
RAP as a novel therapeutic to promote remyelination after MS demyelinating event$353,106
R43 · FY2015 · NS · contact PI
RAP as a therapeutic compound for neuronal regeneration after spinal cord injury$80,122
R41 · FY2015 · NS · contact PI
RAP as a therapeutic compound for neuronal regeneration after spinal cord injury$224,952
R41 · FY2014 · NS · contact PI
RAP as a therapeutic compound for neuronal regeneration after spinal cord injury$24,982
R41 · FY2014 · NS · contact PI